Comparison between curative concurrent chemoradiotherapy followed by adjuvant chemotherapy and curative concurrent chemoradiotherapy alone in patients with locally advanced cervical carcinoma: a meta-analysis

Objective: In the studies of locally advanced cervical carcinoma (LACC), the efficacy of adjuvant chemotherapy (ACT) after curative concurrent chemoradiotherapy (CCRT) has not been clearly investigated. This paper aimed to evaluate the impact of CCRT followed by ACT compared with the impact of CCRT alone in the treatment of LACC. Data sources, methods of study selection: The Web of Science, Cochrane Library, EMBASE, and PubMed were systematically reviewed to find eligible studies up to 28 February 2020. The pooled analysis was conducted through random- or fixed-effect models. Clinical endpoints such as overall survival (OS), progression-free survival (PFS), local failure rate (LFR), distant metastasis (DM), as well as adverse events (AEs) were examined as evaluation indexes. Tabulation, integration and results: Three retrospective studies and two randomized trials were enrolled in this meta-analysis comprising 1172 patients (CCRT arm: 588; CCRT + ACT arm: 584). No significant differences were discovered in OS (hazard ratio [HR] = 0.94, 95% confidence interval [CI]: 0.46, 1.94, p = 0.88) and PFS (HR = 0.91, 95% CI: 0.50, 1.67, p = 0.76) between CCRT followed by ACT and CCRT alone. The pooled RRs for LFR (RR = 0.64, 95% CI: 0.44, 0.92, p = 0.02) and DM (RR = 0.50, 95% CI: 0.35, 0.71, p < 0.05) showed that the application of CCRT followed by ACT decreased LFR and DM compared with CCRT alone. However, CCRT followed by ACT arm had more acute hematologic toxicities (anemia, neutropenia, thrombocytopenia) and grade 3–4 proctitis (all p < 0.05), than CCRT arm; no statis-tic differences were found in late toxicities (cystitis and proctitis) between the two arms (p > 0.05). Conclusion: This study suggested that CCRT followed by ACT did not prolong OS and PFS. It decreased LFR and DM compared with CCRT alone. CCRT followed by ACT raised the incidence of acute hematologic toxicities and proctitis but did not increase late toxicities. Further study is needed in CCRT followed ACT for LACC.

Chemoradiotherapy; Adjuvant chemotherapy; Meta-analysis; Uterine cervical neoplasms

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68: 394–424.

[2] Mountzios G, Soultati A, Pectasides D, Dimopoulos MA, Papadimitriou CA. Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents. Obstetrics and Gynecology International. 2013; 2013: 536765.

[3] Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G, et al. Locally advanced cervical cancer: a study of 5-year outcomes. Indian Journal of Cancer. 2018; 55: 45–49.

[4] Yali Gao, Zishen Zhao, Yamei Gao, Mingyun Zhang, Lina Song. Clinical efficacy of consolidation chemotherapy after concurrent chemoradiotherapy for treatment of young patients with local advanced cervical cancer. Guangxi Medical Journal. 2016; 38: 351–353. (In Chinese)

[5] Zhu J, Zhang Z, Bian D, Chen Q, Hu Q, Ji S, et al. Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma. Medicine. 2020; 99: e18663.

[6] Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradio-therapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Journal of Clinical Oncology. 2008; 26: 5802–5812.

[7] Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. Journal of Clinical Oncology. 2004; 22: 872–880.

[8] Pandya T, Suhag V, Ranjan S, Sunita BS, Pandya S. Toxicity Pro-file of Double-agent Adjuvant Chemotherapy after Concurrent Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer: Comparison with Standard Chemoradiation Protocol. Indian Journal of Medical and Paediatric Oncology. 2019; 40: S6–S12.

[9] Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. Journal of Clinical Oncology. 2011; 29: 1678–1685.

[10] Chen S, Ren T, Wang X, Shen Y, Ning X, He H, et al. Comparison of Concurrent Cisplatin Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy alone in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology, Biology, Physics. 2019; 105S: S52–S52.

[11] Zhang Y, Shi M, Wei L, He J, Zhu Y, Ma W, et al. Safety and Efficacy of Docetaxel plus Cisplatin Versus Cisplatin Concurrent with Radiation in Local Advanced Cervical Cancer: Midterm Results of a Phase III, Multicenter and Randomized Trial. International Journal of Radiation Oncology, Biology, Physics. 2019; 105: E345–E346.

[12] Cheng G, Wu N, Su X, Song H, Li Y, Gu F, et al. Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Chinese Patients with Locally Advanced Cervical Cancer Under-going Platinum-Based Adjuvant Chemotherapy after Concurrent Chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2018; 102S: E618–E618.

[13] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. British Medical Journal. 2009; 339: b2700.

[14] Higgins JP, Green S. Cochrane handbook for systematic re-views of interventions version 5.1.0. The Cochrane Collaboration 2011. 2011. Available at: http://www.cochrane-handbook. org (Accessed: 10 March 2020).

[15] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology. 2010; 25: 603–605.

[16] Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epi-demiologic Reviews. 1992; 14: 154–176.

[17] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal. 2003; 327: 557–560.

[18] Tangjitgamol S, Tharavichitkul E, Tovanabutra C, Rongsriyam K, Asakij T, Paengchit K, et al. A randomized controlled trial com-paring concurrent chemoradiation versus concurrent chemoradi-ation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial. Journal of Gynecologic Oncology. 2019; 30: e82.

[19] Kim YB, Cho JH, Keum KC, Lee CG, Seong J, Suh CO, et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecologic Oncology. 2007; 104: 58–63.

[20] Yavas G, Yavas C, Sen E, Oner I, Celik C, Ata O. Adjuvant carbo-platin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer. International Journal of Gynecologic Cancer. 2019; 29: 42–47.

[21] Tu K, Chen C, Cheng X, Li L. Comparison of the curative ef-fect and safety of consolidation chemotherapy after concurrent chemoradiotherapy with concurrent chemoradiotherapy alone for locally advanced cervical cancer. European Journal of Gynaecological Oncology. 2018; 39: 558–563.

[22] Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New England Journal of Medicine. 1999; 340: 1154–1161.

[23] Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New England Journal of Medicine. 1999; 340: 1137–1143.

[24] Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology. 2000; 18: 1606–1613.

[25] M Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine. 1999; 340: 1144–1153.

[26] Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology. 1999; 17: 1339–1348.

[27] Chatterjee K, SK Mondal, P Sarkar. Adjuvant chemotherapy in the management of cervical cancers- A prospective randomized study. European Journal of Cancer. 2013; 49: S721–S722.

[28] Petrić Miše B, Boraska Jelavić T, Strikic A, Hrepić D, Tomić K, Hamm W, et al. Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyra-diotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy. International Journal of Gynecological Cancer. 2015; 25: 315–319.

[29] Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database of Systematic Reviews. 2014; 2014: CD010401.

[30] Choi IJ, Cha MS, Park ES, Han MS, Choi Y, Je GH, et al. The ef-ficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. Journal of Gynecologic Oncology. 2008; 19: 129–134.

[31] Khalil J, El Kacemi H, Afif M, Kebdani T, Benjaafar N. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy: results from a single institution. Archives of Gynecology and Obstetrics. 2015; 292: 1091–1099.

[32] Mileshkin LR, Narayan K, Moore KN, Rischin D, King M, Kolodziej I, et al. A phase III trial of adjuvant chemotherapy follow-ing chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZ-GOG0902/GOG0274/RTOG1174). Journal of Clinical Oncology. 2014; 32: TPS5632–TPS5632.